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Abstract: Diabetes mellitus is a frequent comorbid conditions among
patients with pneumonia living in the community.
The aim of our study is to evaluate the impact of hospitalization for
pneumonia on early (30 day) and late mortality (1 year) in patients with
type 2 diabetes mellitus.
Prospective comparative cohort study of 203 patients with type 2
diabetes hospitalized for pneumonia versus 206 patients with diabetes
hospitalized for other noninfectious causes from January 2012 to
December 2013 at Policlinico Umberto I (Rome). Enrolled patients
were followed up to discharge and up to 1 year after initial hospital
admission or death.
Overall, 203 patients with type 2 diabetes admitted to hospital for
pneumonia were compared to 206 patients with type 2 diabetes admitted
for other causes (39.3% decompensated diabetes, 21.4% cerebro-
vascular diseases, 9.2% renal failure, 8.3% acute myocardial infarction,
and 21.8% other causes). Compared to control patients, those admitted
for pneumonia showed a higher 30-day (10.8% vs 1%, P< 0.001) and 1-
year mortality rate (30.3% vs 16.8%, P< 0.001). Compared to survi-
vors, nonsurvivor patients with pneumonia had a higher incidence of
moderate to severe chronic kidney disease, hemodialysis, and malnu-
trition were more likely to present with a mental status deterioration, and
had a higher number of cardiovascular events during the follow-up
period. Cox regression analysis found age, Charlson comorbidity index,
pH< 7.35 at admission, hemodialysis, and hospitalization for pneumo-
nia as variables independently associated with mortality.emi, Alessio Farco o Vullo,
d Mario Venditti
(Medicine 95(5):e2531)
Abbreviations: AKI = acute kidney injury, AMI = acute myocardial
infarction, CAP = community acquired pneumonia, CKD = chronic
kidney disease, COPD = chronic obstructive pulmonary diseases,
CVD = cardiovascular disease, DM = diabetes mellitus, ED =
Emergency Department, eGFR = estimated glomerular filtration rate,
PSI = pneumonia severity index, US = United States.
INTRODUCTION
T ype 2 diabetes mellitus (DM) is a major public health issuebecause of its high and rising prevalence worldwide.
According to International Diabetes Federation data, 382
million people worldwide have diabetes and this number is
expected to rise to 592 million by 2035.1 The latest statistics for
the United States (US) indicates that 29.1 million people or
9.3% of the population have DM,2 and DM remains the 7th
leading cause of death in the US.2
Among individuals with DM, cardiovascular disease
(CVD) is the major cause of morbidity and mortality and the
largest contributor to the direct and indirect costs of DM. The
presence of DM significantly increases the risk (2- to 4-fold) for
developing CVD and of dying when CVD is present.3 Despite
multiple efforts and secondary prevention programs, patients
with DM remain a population at high risk of mortality.4,5
Infections are relatively frequent among patients with DM
and may range from rare forms such as malignant external otitis,
rhino-cerebral mucormycosis, or emphysematous infections of
the gallbladder, kidney, and urinary bladder, to more common
ones such as respiratory infections.6 DM is one of the most
common underlying diseases in patients with pneumonia, with a
reported prevalence of 6% to 25% among those with community
acquired pneumonia (CAP).7,8 Several studies have evaluated
outcomes and factors associated with early mortality in patients
with DM affected by pneumonia.9–13 However, it is not well
known whether the hospitalization for pneumonia affects the
long-term survival in patients with type 2 diabetes.
The aim of this prospective cohort study is to evaluate the
early (30-day) and late (1-year) mortality rates in patients with
type 2 diabetes hospitalized for pneumonia compared to patients
with DM hospitalized for other causes, and to assess the factors
independently associated with mortality in this cohort of patients.
METHODSPatient Selection
nducted at the University-Hospital Poli-
rge 1100-bed teaching hospital in Rome.
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(i)Patients with DM admitted to medical wards with diagnosis of
community-onset pneumonia (case group) or with diagnosis
other than pneumonia (control group) through the Emergency
Department (ED) from January 2012 to December 2013 were
consecutively recruited and prospectively followed up. Patients
fulfilling the following criteria were enrolled in the study after
giving written informed consent: age 18 years or over; previous
diagnosis of type 2 DM defined as fasting plasma glucose levels
126mg/dL (7.0mmol/L) or HbA1C 6.5% or 2-hour plasma
levels 200mg/dL (11.1mmol/L) after a 75-g oral glucose
tolerance test or random plasma glucose 200mg/dL
(11.1mmol/L) in a patient with classic symptoms of hypergly-
cemia or hyperglycemic crisis or antidiabetic ongoing
therapy.14 Diagnosis of pneumonia was performed if the follow-
ing criteria were satisfied: signs or symptoms suggesting pneu-
monia: presence of rales, rhonchi, bronchial breath sounds,
fever (>38.0 8C), tachycardia, chills, dyspnea, coughing (with
or without sputum), or chest pain; and presence of new con-
solidation(s) on chest X-ray.
The study included patients having CAP, defined as pneu-
monia diagnosed upon hospitalization in patients who had not
been discharged from an acute care facility within 14 days
preceding the clinical presentation, and patients having health
care associated pneumonia, defined as pneumonia occurring in
patients coming from the community who had attended a
hospital or hemodialysis clinic or received intravenous che-
motherapy in the past 30 days, had been admitted to an acute-
care hospital for at least 2 days or had surgery in the past 90
days, or resided in a nursing home or long-term care facility.15,16
Patients were excluded from the study if one of the
following criteria was applied: radiographic evidence of a
preexisting infiltrates, criteria for hospital-acquired pneumonia,
pregnancy or breastfeeding, documented severe allergy to anti-
biotics, type 1 DM diagnosis, diagnosis of rapidly fatal disease
according to McCabe classification,17 or refusal to sign
informed consent. The control group was represented by
patients with DM consecutively admitted in our hospital
through the ED for causes other than infection during the same
period of admission of the cases (January 2012–December
Falcone et al2013). The present study was conducted according to the
principles stated in the Declaration of Helsinki and was
approved by the local research ethics committee.
Baseline Assessment and Follow-Up
Data on demographic characteristics, comorbidities, anti-
biotic, and concomitant therapies were collected; for patients
with pneumonia, severity of illness at presentation was quanti-
fied by the pneumonia severity index (PSI) and CURB-65
(confusion, urea >7mmol/L, respiratory rate 30 breaths per
minute, and blood pressure 90/60mmHg) score.18 Charlson
comorbidity index, a recognized method for classifying comor-
bid conditions which might alter the risk of mortality, was
calculated for all patients when they were admitted to ED, using
the same criteria.19 Hypertension, history of coronary heart
disease, dyslipidemia, and chronic obstructive pulmonary dis-
eases (COPD) were defined as previously described.20,21 Base-
line treatments were defined according to the patients’
pharmacological history. At hospital admission all patients with
pneumonia underwent physical examination, laboratory inves-
tigations, arterial blood gases analysis, and chest X-ray.According to Kidney Disease Outcomes Quality Initiative
guidelines, chronic kidney disease (CKD) was defined as the
presence of one of the following criteria:
2 | www.md-journal.comor M
priat
struc
Cokidney damage for 3 months, evaluated as structural or
functional abnormalities of the kidney with or without
decreased estimated glomerular filtration rate (eGFR),
manifest by either pathological abnormalities or markers
Medicine  Volume 95, Number 5, February 2016of kidney damage, including abnormalities of the
composition of the blood or the urine or abnormalities
in the imaging tests;
(ii) eGFR <60mL/min/1.73m
2 for 3 months, with or
without kidney damage.
CKD stage has been defined as: stage 1 in presence of
kidney damagewith normal or increased eGFR (eGFR90mL/
min/1.73m2); stage 2 in presence of kidney damage with mild
decrease of eGFR (eGFR 60–89mL/min/1.73m2); stage 3 in
presence of moderate decrease of eGFR (eGFR 30–59mL/min/
1.73m2); stage 4 in presence of severe decrease of eGFR (eGFR
15–29mL/min/1.73m2); and stage 5 in presence of kidney
failure (eGFR<15mL/min/1.73m2 or dialysis).22 Septic shock
was defined according to the Surviving Sepsis Campaign
criteria as sepsis-induced hypotension persisting despite ade-
quate fluid resuscitation.23 Diagnosis of malnutrition was based
on the presence of one or more of the following criteria: weight
loss 5% in 1 month or 10% in 6 months; body mass index
<21 kg/m2; serum albumin concentrations <35 g/L; and mini
nutritional assessment score <17.24
Microbiological examinations performed on sputum, urine,
and blood during the first 24 hours after admission and according
to standards of practice were evaluated for assessment of
microbial etiology. Clinical isolates obtained from patients were
identified in the Microbiology Laboratory of our hospital using
the automatic system VITEK 2 (bioMe´rieux Inc., Hazelwood,
MO). Microbiological determinations were performed as pre-
viously described.25 Antibiotic therapy was initiated in the ED
following the hospital guidelines and/or the advice of an infec-
tious diseases specialist. Patients included in study or control
groups were followed up to the end of hospitalization and for 1
year after discharge or until death. Follow-up assessment was
performed in all patients by means of telephone interviews,
evaluation during a new hospitalization, or ambulatory visit when
possible. A fatal or nonfatal ischemic cardiovascular event during
follow-up was defined as the occurrence of an acute myocardial
infarction (AMI) or ischemic stroke.20
Study Endpoint and Statistical Analysis
The study endpoint was to compare the occurrence of death
during the first 30 days and 1 year after hospital admission
discharge between cases (patients with DM admitted for pneu-
monia) and controls (patients with DM admitted for other
causes). The results obtained were analyzed using commercially
available statistical software packages (SPSS, version 20.0;
SPSS, Inc., Chicago, IL and R, version 3.0.2; R development
core team, Vienna, Austria).
The sample size was planned using a log-rank test for
comparing mortality rate in patients with DM hospitalized or
not for pneumonia. Assuming equal allocation between groups,
a hazard ratio equal to 2, an incidence rate of 22% at 1 year,26 we
evaluated that a total sample size of 397 would yield a power of
at least 90% at a fixed a type I error rate of 5%. Estimation of
drop-out rate was not established a priori. To detect significant
differences between groups, we used the Chi-square test or
Fisher exact test for categorical variables and the 2-tailed t-testann–Whitney test for continuous variables, when appro-
e. Survival curves for time-to-event variables were con-
ted with the use of Kaplan–Meier estimates based on all
pyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
available data and were compared with the use of the log-rank
test. In a multivariate analysis of survival, the Cox regression
model was used to determine the effects of different variables on
overall survival. All variables were considered for the multi-
variate Cox model analysis. At multivariate analysis the pre-
dictors were selected via a stepwise selection procedure
optimizing the Akaike Information Criterion. The proportion-
ality of hazards assumption for the Cox model has been checked
using plots of Schoenfeld residuals. Statistical significance was
established at 0.05. All reported P values are 2-tailed.
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A total of 409 patients with DM were included in the study.
Out of these, 203 were patients with DM admitted to hospital for
TABLE 1. Characteristics of Diabetic Patients by Study Groups
Variable
Diabetic Patien
for Pneumonia
Demographic data
Males 130 (64
Age, median (IQR), year 75 (67
Duration of diabetes, median (IQR) year 13 (11
Comorbid conditions
Chronic heart failure 58 (28
Chronic hepatitis 12 (5.9
Chronic kidney failure 66 (32
Hemodialysis 8 (3.9
Dyslipidemia 85 (41
COPD 68 (33
Previous cardiovascular events 94 (46
History of atrial fibrillation 36 (17
Charlson comorbidity index, median (IQR) 3 (2–
Reasons for hospitalization
Pneumonia 203 (10
Decompensated diabetes –
Acute myocardial infarction –
Cerebrovascular diseases –
Renal failure –
Others –
Clinical features at admission
pH< 7.35 12 (8.9
PSI II to III class 26 (12
PSI IV class 129 (63
PSI V class 48 (23
CURB-65 I class 43 (21
CURB-65 II class 86 (42
CURB-65 III class 74 (36
Therapy
Metformin therapy 89 (43
Insulin therapy 64 (31
Statin therapy 84 (41
30-day mortality 22 (10
90-day mortality 35 (17
180-day mortality 49 (24
1-year mortality

60 (33
P< 0.05 is considered statistically significant, P< 0.001 is considered s
disease, CURB-65¼ confusion, urea >7 mmol/L, respiratory rate 30 brea
range, PSI¼ pneumonia severity index, SD¼ standard deviation.
1 year mortality rate was calculated on 180 patients admitted for pneu
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.pneumonia, while 206 were patients with DM admitted for other
causes (39.3% decompensated diabetes, 21.4% cerebrovascular
diseases, 9.2% renal failure, 8.3% AMI, and 21.8% other non-
infectious causes). Comparison between cases and controls is
summarized in Table 1. The median duration of DM diagnosis
was 13 (interquartile range [IQR] 11–15) years among patients
with DM with pneumonia and 12 (IQR 10–15) years among
patients with DM without pneumonia; this difference was not
statistically significant. No differences in demographic charac-
teristics were recorded between the study groups, but patients
with DM admitted for pneumonia showed a higher frequency of
chronic heart failure, CKD, and COPD compared to patients with
Decreased Survival of Diabetic Patients After PneumoniaDM admitted for other causes. Table S1, http://links.lww.com/
MD/A676 shows a comparison of cases and controls with a 3rd
group of patients without diabetes admitted for pneumonia: as
ts Admitted
N¼ 203, %
Diabetic Patients Without
Pneumonia N¼ 206, % P Value
) 127 (61.7) 0.617
–82) 74 (66–80.25) 0.697
–15) 12 (10–15) 0.250
.6) 23 (11.2) <0.001
) 11 (5.3) 0.802
.5) 48 (23.3) 0.038
) 5 (2.4) 0.383
.9) 69 (33.5) 0.080
.5) 23 (11.2) <0.001
.3) 88 (42.7) 0.465
.7) 31 (15.1) 0.476
4) 3 (3–4) 0.033
0) –
81 (39.3)
17 (8.3)
44 (21.4)
19 (9.2)
45 (21.8)
) 12 (8.7) 0.956
.8) –
.5) –
.6) –
.2) –
.4) –
.5) –
.8) 98 (50.4) 0.449
.5) 84 (40.8) 0.052
.4) 68 (33) 0.080
.8) 2 (1) <0.001
.2) 15 (7.3) 0.001
.1) 18 (8.7) <0.001
.3) 32 (16.8) <0.001
tatistically highly significant. COPD¼ chronic obstructive pulmonary
ths per minute, and blood pressure 90/60 mmHg, IQR¼ interquartile
monia and 190 control patients.
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expected, patients with DM admitted for pneumonia had a higher
incidence of chronic kidney failure, dyslipidemia, and previous
cardiovascular events compared to patients without DM admitted
for pneumonia.
Among patients with DM admitted for pneumonia, the
etiologic microorganism was identified in 65 (32%) patients.
The most frequent causative microorganisms were Staphylo-
coccus aureus (24.6%), Streptococcus pneumoniae (23%),
Pseudomonas aeruginosa (10.8%), Klebsiella pneumoniae
(9.2%), Mycoplasma pneumoniae (6.2%), Haemophilus influ-
enzae (4.6%), Escherichia coli (4.6%), and others (17%).
Antibiotic therapy of patients with DM admitted for pneumonia
was the following: 34 (16.7%) patients were treated with b
lactam/b lactamase inhibitor plus macrolides or fluoroquino-
lone, 57 (28.1%) patients with cephalosporin plus macrolides or
fluoroquinolone, 29 (14.3%) patients with b lactam/b lactamase
inhibitor alone, 27 (13.3%) patients with fluoroquinolone alone,
24 (11.8%) patients with cephalosporin alone, 6 (3%) patients
with macrolides alone, 6 (3%) patients with carbapenem plus
glycopeptide, and 20 (9.8%) patients with other therapies.
Twenty-three (11.3%) patients with DM admitted for
pneumonia and 16 (7.8%) control patients were lost to 1-year
follow-up. Patients with DM admitted for pneumonia showed a
higher 30-day (10.8% vs 1%, P< 0.001), 90-day (17.2% vs
7.3%, P¼ 0.001), 180-day (24.1% vs 8.7%, P< 0.001), and 1-
year mortality rate (30.3% vs 16.8%, P< 0.001) compared to
those admitted for other causes. Figure 1 shows Kaplan–Meier
analysis on estimated survival within 1 year after admission of
patients with DM admitted for pneumonia compared to controls.
Clinical features and outcomes of survivors and nonsurvi-
vors patients with DM within 30 days and 1 year after hospi-
talization for pneumonia are reported in Tables 2 and 3,
respectively. Patients who died at 30 days showed a higher
incidence of hospitalization in the previous 3 months, intravas-
cular devices, COPD, malnutrition, and previous cardiovascular
events; furthermore, nonsurvivors within 30 days had a higher
incidence of health care associated pneumonia, PSI class V,
Falcone et almultilobar pneumonia, metabolic acidosis (pH< 7.35) at
admission, and septic shock. Interestingly, metformin therapy
was more frequent in patients who survived. Patients who died
FIGURE 1. Kaplan–Meier plot showing long-term survival after
discharge among patients with diabetes admitted for pneumonia
(N¼203, the green line) and diabetic control patients (N¼206,
the blue line); P<0.001 between the study groups.
4 | www.md-journal.comat 1-year follow-up had a higher incidence of moderate to severe
CKD, hemodialysis, malnutrition, and were more likely to
present with a mental status deterioration and a PSI V class
and CURB-65 class III. Patients who died during the follow-up
period had a higher incidence of cardiovascular events com-
pared to survivors (31.7% vs 10%, P< 0.001).
To evaluate the predictors independently associated with
1-year mortality, a Cox regression analysis was performed.
Table 4 shows univariate and multivariate Cox regression
analyses about effect of different variables on overall survival
during follow-up period. Age, Charlson comorbidity index,
pH< 7.35 at admission, hemodialysis, and hospitalization for
pneumonia resulted factors independently associated with 1-
year mortality.
DISCUSSION
The relevant finding of our prospective study is that among
patients with type 2 DM hospital admission for pneumonia is
associated with higher mortality compared to hospitalization for
other noninfectious illnesses. Diabetic subjects admitted for
pneumonia had higher mortality within the first 30 days, and
one third died at 1 year.
The 30-day mortality rate (10.9%) observed in our popu-
lation is similar to that previously reported. In a retrospective
observational study, Hirata et al9 studied 185 patients with DM
hospitalized for the first time for pneumonia and the 30-day
mortality was 7.6%. Similarly, Di Yacovo et al10 in a prospec-
tive study reported an in-hospital mortality of 7.2% among 526
patients with DM hospitalized for CAP, while mortality was as
high as 17% in a further study on 106 patients with DM.7
Conversely, very few data are available about the long-term
mortality. Lepper et al8 found a 90-day mortality of 14.5%
among 1114 patients with type 2 diabetes with CAP, signifi-
cantly higher than mortality observed in patients without dia-
betes. A retrospective study by Yende et al27 demonstrated that
preexisting DM is associated with a higher risk of death
following hospitalization for CAP. More recently, a prospective
study recorded the causes of death of 153 patients hospitalized
for CAP after a median of 5 years and 11 months and the
mortality rates at the end of follow-up were 54% among patients
with DM and 10% among patients without DM (however,
diabetic population was represented only by 22 patients, without
distinction between type-1 and type-2 DM).28
The strength of our study is that we designed a prospective
cohort study to investigate whether pneumonia is an event that
increases short and long-term mortality in a well-defined popu-
lation of patients with DM, following the subjects overtime up
to 1 year after hospital admission. According to our findings,
hospitalization for pneumonia increases the risk of death in
patients with type 2 diabetes, and the Cox regression analysis
confirmed that pneumonia is a factor independently associated
with 1-year mortality. This is an important finding because a
change in causes of death was observed in patients with DM in
recent years. According to data of National Health Interview
Survey, 3-year CVD death rates declined by 9.5 deaths per 1000
person-years during the period 1997 to 1998 to 5.6 per 1000
person-years during the period 2003 to 20044 in US, with a 40%
decrease in CVD mortality. Another recent study showed that
the rate of 5 major complications, including AMI, stroke,
amputation, end renal stage disease, and death from hypergly-
Medicine  Volume 95, Number 5, February 2016cemic crisis, significantly decline between 1990 and 2010.5
The exact underlying pathophysiological mechanisms
responsible for the higher long-term mortality in patients with
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 2. Comparison of Diabetic Patients With Pneumonia Survived or Not Survived at 30-day of Hospitalization
Variable Nonsurvivors n¼ 22, % Survivors n¼ 181, % P Value
Demographic data
Males 13 (59.1) 117 (64.6) 0.608
Hospitalization in the previous 3 months 12 (54.5) 32 (17.7) <0.001
Prior antibiotic therapy (last 30 days) 3 (13.6) 24 (13.3) 0.961
Intravascular devices 6 (27.3) 10 (5.5) <0.001
Comorbid conditions
Chronic heart failure 6 (27.3) 52 (28.7) 0.886
Chronic hepatitis 1 (4.5) 11 (6.1) 0.774
Moderate to severe renal disease 10 (45.5) 56 (30.9) 0.170
Dyslipidemia 6 (27.3) 79 (43.6) 0.142
COPD 1 (4.5) 67 (37) 0.002
Malnutrition 5 (22.7) 7 (3.9) <0.001
Previous cardiovascular events 16 (72.7) 78 (43.1) 0.008
History of atrial fibrillation 2 (9.1) 34 (18.8) 0.261
Characteristics of pneumonia
CAP 8 (36.4) 126 (69.6) 0.002
HCAP 14 (63.6) 55 (30.6) 0.002
Pleural effusion 11 (50) 67 (37) 0.237
Bilateral pneumonia 11 (50) 60 (33.1) 0.118
Multilobar pneumonia 13 (59.1) 55 (30.4) 0.007
Clinical and laboratory findings at admission
Dyspnea 15 (68.2) 94 (52.5) 0.149
Tachypnea (30 breaths/min) 8 (36.4) 50 (27.6) 0.392
Chest pain 1 (4.5) 4 (2.2) 0.511
Mental status deterioration 6 (27.3) 7 (3.9) <0.001
Leukocytosis (leukocytes 10.000 /mL) 15 (68.2) 117 (64.6) 0.742
pH< 7.35 9 (40.9) 9 (5) <0.001
Increased troponin 18 (81.8) 135 (74.6) 0.457
Hyperglycemia at admission (11 mmol/L) 8 (36.4) 82 (45.3) 0.500
PSI classes 0.040
Class II to III 1 (4.5) 25 (13.8)
Class IV 11 (50) 118 (65.2)
Class V 10 (45.5) 38 (21)
CURB-65 classes 0.127
Class I 2 (9.1) 41 (22.7)
Class II 8 (36.4) 78 (43.1)
Class III 12 (54.5) 62 (34.2)
Therapy
Metformin therapy 3 (13.6) 86 (47.5) 0.002
Insulin therapy 6 (27.3) 58 (32) 0.649
Statin therapy 6 (27.3) 78 (43.1) 0.155
Septic shock 9 (40.9) 3 (1.7) <0.001
P< 0.05 is considered statistically significant, P< 0.001 is considered statistically highly significant. CAP¼ community acquired pneumonia,
urea
mon
Medicine  Volume 95, Number 5, February 2016 Decreased Survival of Diabetic Patients After PneumoniaDM admitted to hospital for pneumonia are not well known, but
the following explanations could be proposed: pneumonia may
be a trigger which accelerates preexisting chronic diseases,
through the activation of a persisting proinflammatory status
and the precipitation of fatal cardiovascular events; and pneu-
monia itself and/or antibiotic therapies could determine a
worsening of renal function increasing the risk of morbidity
and medium long-term mortality.
It is known that, in patients with CAP, cytokine concen-
COPD¼ chronic obstructive pulmonary disease, CURB-65¼ confusion,
90/60 mmHg, HCAP¼ health care associated pneumonia, PSI¼ pneutrations (TNFa, IL-6, and IL-10) are high at hospital admission,
decline rapidly over the 1st few days, but persist elevated for
several weeks after resolution of clinical signs of
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.inflammation.29 Hemostasis markers, in particular thrombin–
antithrombin complexes, continue to be elevated at hospital
discharge;30 of interest, these alterations have been observed
even in subjects who experienced less severe illness during the
hospital course or to those that appeared to have recovered
clinically.30 Both higher cytokines concentration and high
hemostasis markers at hospital discharge are associated with
higher risk of death over 1 year, particularly due to acute
deterioration of CVD.30,31 Platelets activation, vasoconstric-
>7 mmol/L, respiratory rate30 breaths per minute, and blood pressure
ia severity index.tion, systemic inflammation, and increased metabolic demand
strongly support a role for acute infections in triggering acute
cardiovascular events.32 As a matter of fact, in our study
www.md-journal.com | 5
TABLE 3. Comparison of Diabetic Patients With Pneumonia Survived or Not Survived at 1 year After Hospitalization
Variable 1 year Nonsurvivors n¼ 60, % 1 year Survivors n¼ 120, % P Value
Demographic data
Males 37 (61.7) 80 (66.7) 0.507
Hospitalization in the previous 3 months 23 (38.3) 20 (16.7) 0.001
Prior antibiotic therapy (last 30 days) 6 (10) 16 (13.3) 0.520
Intravascular devices 8 (13.3) 8 (6.7) 0.138
Comorbid conditions
Chronic heart failure 18 (30) 37 (30.8) 0.909
Chronic hepatitis 4 (6.7) 8 (6.7) 1.000
Moderate to severe renal disease

27 (45) 31 (25.8) 0.009
Dyslipidemia 22 (36.7) 55 (45.8) 0.241
COPD 15 (25) 44 (36.7) 0.116
Malnutrition 10 (16.7) 2 (1.7) <0.001
Previous cardiovascular events 32 (53.3) 53 (44.2) 0.246
History of atrial fibrillation 8 (13.3) 25 (20.8) 0.220
Characteristics of pneumonia
CAP 27 (45) 88 (73.3) <0.001
HCAP 33 (55) 32 (26.7) <0.001
Pleural effusion 28 (46.7) 44 (36.7) 0.197
Bilateral pneumonia 31 (51.7) 35 (29.2) 0.003
Multilobar pneumonia 28 (46.7) 34 (28.6) 0.015
Clinical and laboratory findings at admission
Mental status deterioration 9 (15) 3 (2.5) 0.002
pH< 7.35 10 (16.7) 7 (5.8) 0.019
Increased troponin 51 (85) 85 (70.8) 0.037
Hyperglycemia at admission (11 mmol/L) 25 (41.7) 54 (45) 0.671
PSI classes <0.001
Class II to III 4 (6.7) 20 (16.7)
Class IV 29 (48.3) 82 (68.3) 0.017
Class V 27 (45) 18 (15)
CURB-65 classes
Class I 8 (13.3) 34 (28.3)
Class II 23 (38.3) 51 (42.5)
Class III 29 (48.3) 35 (29.2)
Therapy
Metformin therapy 22 (36.7) 57 (47.5) 0.167
Insulin therapy 20 (33.3) 37 (30.8) 0.734
Statin therapy 22 (36.7) 53 (44.2) 0.336
Cardiovascular events during follow-up period 19 (31.7) 12 (10) <0.001
P< 0.05 is considered statistically significant, P< 0.001 is considered statistically highly significant. CAP¼ community acquired pneumonia,
COPD¼ chronic obstructive pulmonary disease, CURB-65¼ confusion, urea>7 mmol/L, respiratory rate30 breaths per minute, and blood pressure
mon
Falcone et al Medicine  Volume 95, Number 5, February 2016cardiovascular events during the follow-up period were more
frequent in patients who died. Respiratory tract infections have
been directly associated with an increased risk for vascular
disease, including AMI,33,34 and we found a significant associ-
ation between platelet activation, thromboxane A2 production,
and AMI in patients with pneumonia.20 Furthermore, we
recently showed that chronic aspirin use, probably reducing
the occurrence of cardiovascular complications, is associated
with lower mortality rate in this setting of patients.21
Another deleterious effect of pneumonia in patients with
DM may be related to the worsening of renal function. Associ-
ation between CKD and acute community acquired infections
90/60 mmHg, HCAP¼ health care associated pneumonia, PSI¼ pneu
Including patients undergoing hemodialysis.has been reported. In the retrospective study by McDonald
et al,35 a high incidence of CAP and sepsis was observed among
patients with DM with CKD (manifested as reduced glomerular
6 | www.md-journal.comfiltrate and/or history of proteinuria). Murugan et al36 found an
incidence of acute kidney injury (AKI) of 34% in patients with
CAP, even among those without severe sepsis or severe CAP.
Moreover, a further study revealed that, compared with patients
with normal kidney function, older patients with DM with eGFR
<30 mL/min/1.73 m2 have a higher 28- and 90-day mortality
following CAP.37 A retrospective analysis of 2 multicenter
cohorts confirmed that DM increases the risk of AKI in patients
with CAP (30.2% vs 22.9% for subjects with and without
diabetes, P¼ 0.007) and this association remained significant
when adjusted for age, sex, and race (P¼ 0.02).27 Furthermore,
AKI may also be related to toxicity of antibiotic therapies. This
ia severity index.aspect is of particular importance in patients with pneumonia
due to MDR pathogens who need potentially toxic antibiotics
like glycopeptides, aminoglycosides, colistin, or others. In this
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 4. Univariate and Multivariate Cox Regression Analysis About Effects of Different Variables on Overall Survival During
Follow-Up
Univariate Analysis Unadjusted
Effects of Variables
Multivariate Analysis Adjusted
Effects of Variables
HR 95.0% CI for HR HR 95.0% CI for HR
Lower Upper P-Value Lower Upper P-Value
Hospitalization for pneumonia 2.275 1.481 3.494 <0.001 1.805 1.134 2.874 0.012
Age 1.051 1.029 1.074 <0.001 1.057 1.032 1.082 <0.001
pH< 7.35 1.918 1.043 3.529 0.036 3.385 1.768 6.482 <0.001
Hemodialysis 4.359 2.105 9.023 <0.001 3.701 1.678 8.164 0.001
Charlson comorbidity index 1.360 1.204 1.538 <0.001 1.225 1.059 1.418 0.006
Gender (male) 1.110 0.730 1.687 0.626
Renal insufficiency 2.390 1.583 3.606 <0.001
Chronic hepatitis 1.339 0.619 2.893 0.458
Dementia 1.191 0.377 3.763 0.766
Pleural effusion 2.140 1.372 3.338 0.001
Malnutrition 4.626 2.333 9.171 <0.001
Medicine  Volume 95, Number 5, February 2016 Decreased Survival of Diabetic Patients After Pneumoniaview, we also found the hemodialysis as an independent factor
for mortality in patients with DM. Hemodialysis may affect
clearance of medications, including antibiotics, and in critically
ill patients with pneumonia and kidney failure drug disposition
are likely to be altered from that observed in healthy volun-
teers,38 with possible antibiotic underdosing on the site
of infection.
Although it was not an endpoint of our study, we observed
that hyperglycemia at admission was not associated with
increased mortality in patients with pneumonia. This result
may be explained by the fact that we analyzed a population
of patients with type 2 diabetes requiring hospitalization, and
the presence of hyperglycemia was very common. Data about
the role of hyperglycemia are contrasting: Kornum et al12
reported that a high serum glucose level at admission was a
predictor of death among patients with DM but the impact of
hyperglycemia on mortality was lower in patients with DM than
in nondiabetic individuals. On the same hand, Hirata et al9
found that serum glucose levels on admission were not inde-
pendently associated with mortality. A further study did not find
correlation between mortality and the degree of hyperglycemia
on admission.39 As consequence, hyperglycemia does not
appear a determinant of unfavorable outcome in patients with
DM admitted for pneumonia.
Our study has some limitations. First, our analysis included
elderly patients requiring hospitalization, and therefore our data
cannot be extrapolated to a younger population of patients with
DM affected by pneumonia. Second, our study is a cohort study
conducted in a single center, and study groups are not very
large. Consequently, the results need to be confirmed in multi-
center studies with a higher number of patients. Third, a
percentage of patients (9.5% of all patient population) were
lost to follow-up and the estimation of drop out was not
calculated a priori. Although the above-mentioned limitations,
the strength of the study is its prospective design and the
consecutively recruitment of the patients, which reduce poten-
CI¼ confidence interval, HR¼ hazard ratio.tial bias in the interpretation of data, and the fact that the
characteristics of our patients are representative of the popu-
lation of patients with hospitalized patients with DM observed
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.in clinical practice. On this hand, we believe that our obser-
vations may be generalized to elderly patients with DM needing
hospitalization. Nevertheless, larger studies may be necessary
to validate our findings.
In conclusion, we have shown that hospitalization for
pneumonia is associated with poor 1-year survival in patients
with type 2 diabetes, and it appears to be a major determinant of
long-term outcome in these patients. The mechanism is likely to
be due to worsening of preexisting CVD and higher risk of
kidney injury. These findings suggest to physicians and general
practitioners a diligent clinical control of patients with type 2
diabetes discharged after hospitalization for pneumonia, includ-
ing frequent ambulatory visits, monitoring of renal function,
and prompt hospitalization in presence of any sign or symptom
of CVD at least up to 1 year after the episode of pneumonia.
Further studies are necessary to better elucidate the underlying
mechanisms responsible for the excess of mortality correlated to
pneumonia in patients with type 2 diabetes.
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